Prescription Drug Price Relief Act of 2025

This bill creates a process for the Secretary of Health and Human Services to determine if brand name drug prices exceed those in five reference countries (Canada, UK, Germany, France, and Japan). If a drug is deemed excessively priced, the government will terminate the manufacturer's exclusivity rights and allow any company to produce a generic version under an open, non-exclusive license with a reasonable royalty. Drug manufacturers must submit detailed annual reports on pricing, costs, and revenues, with penalties for noncompliance. The Secretary will maintain a public database of excessive price determinations and report annually to Congress. This directly impacts brand name drug manufacturers, generic producers, and patients who purchase prescription drugs.